MDM2(phospho-Ser166) Antibody

Catalog Number:

11550

Amount:

100μg

Price:

$319

Swiss-Prot No:

Swiss-Prot: Q00987
NCBI Protein: NP_002383.2

Form of Antibody:

Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability:

Immunogen:

Peptide sequence around phosphorylation site of Serine 166 (A-I-S(p)-E-T) derived from Human MDM2.

Purification:

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi

Specificity/Sensitivity:

The antibody detects endogenous level of MDM2 only when phosphorylated at serine 166.

Applications:

WB IHC IF

Background:

This gene is a target gene of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of this gene can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants have been isolated from both tumor and normal tissues

Haupt, Y. et al. (1997) Nature 387, 296-299.
Zhou, B. P. et al. (2001) Nat. Cell Biol. 3, 973-981.
Grossman, S. R. et al. (1998) Mol. Cell 2, 405-415.
Mayo, L.D. and Donner, D.B. (2001) Proc. Natl. Acad. Sci. USA 98, 11598-11603.

References:

appl_detail:

Predicted MW: 90kd
Western blotting: 1:500~1:1000
Immunohistochemistry: 1:50~1:100
Immunofluorescence: 1:100~1:200

Datasheet PDF